<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Incidence and risk factors</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Incidence and risk factors</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Incidence and risk factors</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lee-may Chen, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan S Berek, MD, MMS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara Goff, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Don S Dizon, MD, FACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 03, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H6091373"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Epithelial carcinomas of the ovary, fallopian tube, and peritoneum (EOC) can generally be considered one clinical entity, with some distinctions. The incidence of and risk factors for these carcinomas will be reviewed here. Related topics are discussed in detail separately, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Overview (see  <a class="medical medical_review" href="/z/d/html/83397.html" rel="external">"Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Histopathology (see  <a class="medical medical_review" href="/z/d/html/3241.html" rel="external">"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Histopathology"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical features and diagnosis (see  <a class="medical medical_review" href="/z/d/html/3238.html" rel="external">"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5472.html" rel="external">"Early detection of epithelial ovarian cancer: Role of symptom recognition"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Staging and surgical treatment (see  <a class="medical medical_review" href="/z/d/html/3193.html" rel="external">"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Surgical staging"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adjuvant therapy (see  <a class="medical medical_review" href="/z/d/html/3199.html" rel="external">"Adjuvant therapy of early-stage (stage I and II) epithelial ovarian, fallopian tube, or peritoneal cancer"</a> and  <a class="medical medical_review" href="/z/d/html/3239.html" rel="external">"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tube, and peritoneal cancer"</a>)</p><p></p><p class="headingAnchor" id="H6092134"><span class="h1">INCIDENCE</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ovarian carcinoma</strong> – In 2020, ovarian cancer accounted for an estimated 314,000 new cancer cases and 207,000 deaths worldwide [<a href="#rid1">1</a>]. It is the third most common gynecologic cancer, after cervical and uterine cancer (age standardized incidence for cervical, uterine, and ovarian cancer: 13.3, 8.7, and 6.6 per 100,000 females, respectively).</p><p></p><p class="bulletIndent1">In the United States, there are approximately 19,710 new cases and 13,270 cancer-related deaths each year from ovarian cancer, making it the second most common gynecologic malignancy (uterine cancer is most common), the most common cause of death from a gynecologic cancer, and the fifth leading cause of cancer death in females (lung and bronchus, breast, colon and rectum, and pancreatic cancer are more common) [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1">Based on data from the United States National Cancer Database Surveillance, Epidemiology, and End Results (SEER), approximately 1.3 percent of females in the United States will be diagnosed with ovarian cancer at some point during their lifetime [<a href="#rid3">3</a>]. Incidence rates (per 100,000 population) vary based on race/ethnicity:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Non-Hispanic White American (11.9) </p><p class="bulletIndent2"><span class="glyph">•</span>Hispanic American (10.3)</p><p class="bulletIndent2"><span class="glyph">•</span>Asian American or Pacific Islander (9.4) </p><p class="bulletIndent2"><span class="glyph">•</span>Non-Hispanic Black American (9.2) </p><p class="bulletIndent2"><span class="glyph">•</span>American Indian/Alaska Native (8.1) </p><p></p><p class="bulletIndent1">Incidence rates have been falling from 16.3 per 100,000 females in 1975 to 10.1 per 100,000 in 2016.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fallopian tube carcinoma </strong>–<strong> </strong>Fallopian tube carcinoma had been thought to be uncommon, with an age-adjusted incidence of 0.39 per 100,000 females in the United States [<a href="#rid4">4</a>]. However, the incidence is now thought to be much higher because many high-grade serous carcinomas involving the fallopian tube were formerly classified as advanced ovarian carcinoma but are now thought to have originated in the fallopian tube and spread to the ovary [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peritoneal carcinoma</strong> – Peritoneal carcinoma had also been thought to be uncommon, with an age-adjusted incidence of 0.65 per 100,000 females in the United States [<a href="#rid4">4</a>]. However, the incidence is now thought to be higher because when it involves the ovary, it is indistinguishable from stage III ovarian cancer, which is the stage at which more than 50 percent of serous carcinomas are diagnosed [<a href="#rid6">6</a>].</p><p></p><p class="headingAnchor" id="H6092142"><span class="h1">PROBABLE RISK FACTORS</span><span class="headingEndMark"> — </span>Major risk factors for EOC are discussed below. Risk factors for fallopian tube and peritoneal carcinoma are less well defined than for ovarian carcinoma but have generally been found to be the same.</p><p class="headingAnchor" id="H488066"><span class="h2">Older age</span><span class="headingEndMark"> — </span>The incidence of EOC increases with increasing age. An analysis of data from the Nurses' Health Study found that the risk increased approximately 2 percent for each additional year of age in patients &lt;50 years old and 11 percent in patients ≥50 years old [<a href="#rid7">7</a>].</p><p>The median age at diagnosis of ovarian cancer is 63 years old [<a href="#rid3">3</a>]. The proportion of new cases by age group is:</p><p class="bulletIndent1"><span class="glyph">●</span>&lt;20 years old – 1.3 percent</p><p class="bulletIndent1"><span class="glyph">●</span>20 to 34 – 4.0 percent</p><p class="bulletIndent1"><span class="glyph">●</span>35 to 44 – 6.7 percent</p><p class="bulletIndent1"><span class="glyph">●</span>45 to 54 – 17.5 percent</p><p class="bulletIndent1"><span class="glyph">●</span>55 to 64 – 24.7 percent</p><p class="bulletIndent1"><span class="glyph">●</span>65 to 74 – 22.6 percent</p><p class="bulletIndent1"><span class="glyph">●</span>75 to 84 – 15.3 percent</p><p class="bulletIndent1"><span class="glyph">●</span>&gt;84 – 7.9 percent</p><p></p><p>In patients younger than 20 years of age, germ cell tumors predominate; borderline tumors typically occur in patients in their 30s and 40s; and after age 50 years, EOC predominates [<a href="#rid5">5</a>].</p><p>The average age at diagnosis of ovarian cancer is earlier among patients with a hereditary ovarian cancer syndrome than in sporadic cases. The mean age at diagnosis in patients with Lynch syndrome (hereditary nonpolyposis colon cancer [HNPCC]) was 43 and 49 years in two retrospective studies [<a href="#rid8">8,9</a>]. For <em>BRCA1</em> and <em>BRCA2</em> carriers, the median age at diagnosis was 54.0 and 59.5 years, respectively, in a prospective study [<a href="#rid10">10</a>]. (See <a class="local">'Genetic factors'</a> below.)</p><p class="headingAnchor" id="H6092158"><span class="h2">Early menarche or late menopause</span><span class="headingEndMark"> — </span>Early menarche (before age 12) has been associated with a slightly increased risk of EOC in some, but not all, studies [<a href="#rid11">11-15</a>]. Late age at menopause (after age 52) also appears to be associated with an increased EOC risk (relative risk [RR] 1.46, 95% CI 1.06-1.99 compared with menopause at ≤45 years [<a href="#rid11">11</a>]).</p><p>The risk of EOC appears to increase by 2 to 7 percent for each additional year of ovulation (RR 1.07, 95% CI 1.05-1.08) [<a href="#rid7">7,11</a>]. The proposed mechanism for the association is that early menarche or late menopause increases the total number of ovulations in a patient's lifetime. Repeated ovulation results in minor trauma to the ovarian epithelium, which in turn may lead to malignant transformation [<a href="#rid16">16</a>]. Support for this hypothesis is derived from the observation that patients with periodic suppression of ovulation as a result of oral contraceptive use, pregnancy, or lactation have a lower incidence of EOC.</p><p class="headingAnchor" id="H3729937775"><span class="h2">Genetic factors</span><span class="headingEndMark"> — </span>Studies suggest that a patient who has one first-degree relative with ovarian cancer has an approximate 5 percent risk of ovarian cancer, a 3.5 percent risk if the patient has one second-degree relative, and a 7 percent risk if the patient has two affected relatives [<a href="#rid17">17,18</a>]. Much of this risk may be due to pathogenic variants in <em>BRCA1 </em>and<em> BRCA2 </em>and, to a lesser extent, in other genes associated with ovarian cancer (eg, <em>RAD51C, RAD51D,</em> <em>BRCA1</em>-interacting protein 1 [<em>BRIP1</em>], as well as the mismatch repair genes associated with Lynch syndrome). It is estimated that heritable pathogenic variants account for up to one-quarter of ovarian cancer cases [<a href="#rid19">19-23</a>].</p><p class="headingAnchor" id="H2410255495"><span class="h3">BRCA variants</span><span class="headingEndMark"> — </span>Patients with pathogenic variants of <em>BRCA1 </em>and<em> BRCA2</em> have a greatly increased risk of ovarian and breast cancer  (<a class="graphic graphic_table graphicRef68548" href="/z/d/graphic/68548.html" rel="external">table 1</a>). The evidence establishing the association and the approach to counseling <em>BRCA </em>carriers without a cancer diagnosis are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/758.html" rel="external">"Cancer risks and management of BRCA1/2 carriers without cancer", section on 'Breast and ovarian cancer'</a>.)</p><p class="headingAnchor" id="H2608465512"><span class="h3">Lynch syndrome</span><span class="headingEndMark"> — </span>Lynch syndrome (HNPCC) is associated with several other cancers besides colon cancer: in particular, endometrial, ovarian, urogenital, and other gastrointestinal primaries. Colorectal cancer is the hallmark disease for Lynch syndrome; endometrial cancer is the second most common malignancy in affected patients (occurring in up to 71 percent), but ovarian cancer is also increased in frequency. The lifetime risk of ovarian cancer in patients with Lynch syndrome is up to 38 percent (depending on the genetic variant) compared with approximately 1.5 percent in the general population  (<a class="graphic graphic_table graphicRef52285" href="/z/d/graphic/52285.html" rel="external">table 2</a>). Patients with Lynch syndrome account for 1 percent of ovarian cancers [<a href="#rid24">24</a>] and develop ovarian cancer at a younger age than other patients (age 43 to 48 versus 60 years) [<a href="#rid8">8,9</a>].</p><p>Ovarian cancer in patients with Lynch syndrome is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3224.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and prevention of endometrial and ovarian cancer"</a>.)</p><p class="headingAnchor" id="H3096660578"><span class="h3">Other genetic factors</span><span class="headingEndMark"> — </span><em>BRCA1</em> and <em>BRCA2</em> are among a family of genes in the Fanconi anemia pathway that play a role in homologous recombination. One of the genes for Fanconi anemia, <em>FANCD1</em>, is the same as <em>BRCA2</em>. Data suggest that certain biallelic mutations result in Fanconi anemia, while certain monoallelic genetic variants result in an increased risk of cancers associated with <em>BRCA1</em> [<a href="#rid25">25</a>]. Some genetic variants in this pathway are associated with an increased risk of breast cancer, while others are associated with ovarian cancer [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/z/d/html/109795.html" rel="external">"Clinical manifestations and diagnosis of Fanconi anemia", section on 'Genetics'</a>.)</p><p>In an unselected patient population of ovarian cancer, genetic variants in <em>BRIP1</em>, <em>RAD51C</em>, <em>RAD51D</em>, <em>PALB2</em>, and <em>BARD1</em> were all more frequent in patients with ovarian cancer than in the general population [<a href="#rid27">27</a>]. Compared with the more highly penetrant <em>BRCA1</em> and <em>BRCA2</em>, the lifetime risk for ovarian cancer in <em>BRIP1</em> is approximately 5.8 percent and in <em>RAD51C</em> and <em>RAD51D</em> is 5.2 and 12.0 percent, respectively [<a href="#rid28">28,29</a>]. (See  <a class="medical medical_review" href="/z/d/html/785.html" rel="external">"Overview of hereditary breast and ovarian cancer syndromes"</a>.)</p><p>A variant in a gene that encodes for 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase may be protective against ovarian cancer. HMG-CoA reductase is the rate-limiting step in cholesterol biosynthesis and is the target of statin medications. In a case-control study of over 63,000 patients, patients with genetic variants that led to decreased activity of HMG-CoA reductase had lower rates of epithelial ovarian cancer in both the general population (odds ratio 0.60, 95% CI 0.43-0.83) and in <em>BRCA1</em> and <em>BRCA2</em> mutation carriers (hazard ratio [HR] 0.69, 95% CI 0.51-0.93) [<a href="#rid30">30</a>]. However, this study did not evaluate risk reduction from statins themselves, and further research is needed to determine if a direct association exists.</p><p class="headingAnchor" id="H2936770030"><span class="h2">Nulliparity</span><span class="headingEndMark"> — </span>Parous patients have a reduced risk of developing ovarian cancer. (See <a class="local">'Parity'</a> below.)</p><p class="headingAnchor" id="H6092182"><span class="h2">Endometriosis</span><span class="headingEndMark"> — </span>Endometriosis appears to be associated with some subtypes of EOC (eg, endometrioid, clear cell), but the overall risk appears to be low. This association is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7384.html" rel="external">"Endometriosis in adults: Pathogenesis, epidemiology, and clinical impact", section on 'Ovarian cancer risk'</a>.)</p><p class="headingAnchor" id="H1424529669"><span class="h2">Asbestos</span><span class="headingEndMark"> — </span>A meta-analysis of 18 cohort studies found that exposure to asbestos was associated with an increased risk of death from EOC (standardized mortality ratio 1.77, 95% CI 1.37-2.28) [<a href="#rid31">31</a>]. Talc may be contaminated with asbestos. (See <a class="local">'Talc'</a> below.)</p><p class="headingAnchor" id="H1444648362"><span class="h2">Pelvic radiation</span><span class="headingEndMark"> — </span>A history of pelvic radiation for treatment of primary rectal carcinoma may increase the risk for developing ovarian cancer, although the overall incidence is small. In one cohort study including over 20,000 female patients with rectal cancer, treatment with radiotherapy plus surgery compared with surgery alone was associated with an increase in ovarian cancer (0.98 versus 0.29 percent, adjusted HR 2.08, 95% CI 1.22-3.56) after a five-year latency period [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/z/d/html/14230.html" rel="external">"Approach to the long-term survivor of colorectal cancer", section on 'Second malignancies'</a>.)</p><p class="headingAnchor" id="H1693182930"><span class="h1">UNLIKELY OR CONTROVERSIAL RISK FACTORS</span></p><p class="headingAnchor" id="H2967917027"><span class="h2">Menopausal hormone therapy</span><span class="headingEndMark"> — </span>We believe that EOC risk is not an important factor for consideration by patients who are deciding whether to take menopausal hormone therapy for relief of menopausal symptoms because the absolute risk of EOC with hormone therapy is at most very low. The data regarding the association are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7427.html" rel="external">"Menopausal hormone therapy: Benefits and risks", section on 'Ovarian cancer'</a>.)</p><p class="headingAnchor" id="H4017096832"><span class="h2">Obesity</span><span class="headingEndMark"> — </span>In two systematic reviews, high body mass index appeared to modestly increase ovarian cancer risk (odds ratios [OR] 1.3 [<a href="#rid33">33</a>] and 1.1 [<a href="#rid34">34</a>]), but another systematic review concluded available data were limited and inconsistent, precluding a clear assessment of risk [<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/z/d/html/5370.html" rel="external">"Overweight and obesity in adults: Health consequences", section on 'Cancer'</a>.)</p><p class="headingAnchor" id="H6092190"><span class="h2">Polycystic ovary syndrome</span><span class="headingEndMark"> — </span>Systematic reviews regarding risk of ovarian cancer in patients with polycystic ovary syndrome (PCOS) are inconclusive [<a href="#rid36">36-38</a>]. Confounders include an increased prevalence of infertility and obesity in patients with PCOS.</p><p class="headingAnchor" id="H4273494533"><span class="h2">Family history of breast cancer</span><span class="headingEndMark"> — </span>In families with breast cancer but without ovarian cancer or another hereditary breast and ovarian genetic syndrome, there does not appear to be an increased risk of ovarian cancer. Historically, a personal or family history of breast cancer had been thought to be a risk factor for ovarian cancer; however, pathogenic variants of <em>BRCA1 </em>and<em> BRCA2 </em>appear to account for most of this increased risk. (See <a class="local">'BRCA variants'</a> above and  <a class="medical medical_review" href="/z/d/html/753.html" rel="external">"Genetic testing and management of individuals at risk of hereditary breast and ovarian cancer syndromes"</a>.)</p><p class="headingAnchor" id="H6092263"><span class="h2">Talc</span><span class="headingEndMark"> — </span>There are no conclusive data to support the association between ovarian cancer and genital tract talc use.</p><p>In a 2018 meta-analysis of this issue (24 case-control [13,421 cases] and 3 cohort studies [890 cases, 181,860 person-years]), any perineal talc use was associated with an increased risk of ovarian cancer in case-control studies (OR 1.35, 95% CI 1.27-1.43) but was not statistically significant in cohort studies (OR 1.06, 95% CI 0.90-1.25) [<a href="#rid39">39</a>]. A high risk of recall bias is a major limitation of the case-control studies. Subsequently, a study using prospectively collected pooled data from four cohort studies (n &gt;250,000) to estimate the association between use of powder in the genital area and ovarian cancer (2168 cases) found no significant increase in risk by age 70 [<a href="#rid40">40</a>]. Ovarian cancer incidence in ever-users and never-users was 61 and 55 cases per 100,000 person-years, respectively (estimated risk difference at age 70 years 0.09 percent, 95% CI -0.02 to 0.19; estimated hazard ratio [HR] 1.08, 95% CI 0.99-1.17). HRs for ovarian cancer were not significantly increased for frequent versus never users or for long-term versus never users. Subgroup analyses were conducted for 10 variables; the tests for heterogeneity were not statistically significant for any of these comparisons. Importantly, while the estimated HR for the association between ever use of powder in the genital area and ovarian cancer risk among patients with a patent reproductive tract (intact uterus and no tubal ligation) was 1.13 (95% CI 1.01-1.26), the statistical test for heterogeneity was not significant when this subgroup was compared with patients with nonpatent genital tracts, supporting the conclusion that use of powder in the genital area does not increase ovarian cancer risk. Although larger than previous analyses, this study may have been underpowered to detect true small increases or decreases in cancer risk. A limitation of this study was that the type of powder could not be ascertained, but the increase in HR for ovarian cancer in older cohorts (who were more likely to have used talc powder contaminated with asbestos) was statistically nonsignificant (HR 1.09, 95% CI 0.99-1.19).</p><p>The US Food and Drug Administration states that studies have not conclusively demonstrated a link between talc and ovarian cancer [<a href="#rid41">41,42</a>]. An International Agency for Research on Cancer monograph concluded that perineal use of talc-based body powder is possibly carcinogenic to humans [<a href="#rid43">43</a>]. Health Canada issued a warning in 2019 regarding use of talc as a possible cause of ovarian cancer, advising health care professionals to tell patients to avoid female genital exposure to products containing talc [<a href="#rid44">44</a>]. </p><p class="headingAnchor" id="H1262029627"><span class="h2">Cigarette smoking</span><span class="headingEndMark"> — </span>In a systematic review, current or past smoking appeared to increase the risk of mucinous ovarian cancer (relative risk [RR] 2.1, 95% CI 1.7-2.7) but not other types of EOC (serous, endometrioid, clear cell) [<a href="#rid45">45</a>]. The risk increased with increasing levels of cigarette smoking. Smoking also decreased survival in patients with ovarian cancer [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H3889739857"><span class="h2">Diet</span><span class="headingEndMark"> — </span>Many studies have addressed the role of diet in EOC risk, but high-quality data are not available and no dietary recommendations to avoid EOC risk can be made at this time. Consumption of dairy products [<a href="#rid47">47-49</a>], soy [<a href="#rid50">50</a>], fat from animal sources [<a href="#rid51">51</a>], various vitamin supplements [<a href="#rid52">52,53</a>], nitrates [<a href="#rid53">53</a>], red meat [<a href="#rid53">53</a>], fruits and vegetables [<a href="#rid53">53</a>], tea [<a href="#rid54">54,55</a>], and a healthy or unhealthy diet [<a href="#rid56">56</a>] are among the dietary factors that have been studied without clear findings.</p><p class="headingAnchor" id="H6092287"><span class="h2">Exercise</span><span class="headingEndMark"> — </span>There is no clear relationship between physical activity and ovarian cancer risk [<a href="#rid7">7,57</a>]. At best, there is a modest decrease in risk in patients with high levels of activity [<a href="#rid58">58-60</a>]; however, at least two studies suggested an increase in risk with vigorous activity [<a href="#rid61">61,62</a>].</p><p class="headingAnchor" id="H722104619"><span class="h2">Infertility and infertility treatment</span><span class="headingEndMark"> — </span>Infertility and infertility treatment do not appear to be independent risk factors for EOC. An association between infertility and EOC observed in some studies may have been related to endometriosis or nulliparity. The evidence regarding infertility and infertility treatment and ovarian cancer risk is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7407.html" rel="external">"Overview of ovulation induction", section on 'Cancer risks'</a> and  <a class="medical medical_review" href="/z/d/html/6788.html" rel="external">"Assisted reproductive technology: Pregnancy and maternal outcomes", section on 'Ovarian cancer and borderline tumors'</a>.)</p><p class="headingAnchor" id="H291890"><span class="h2">Other</span></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis found no association between alcohol intake and the risk of EOC [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Population-based studies have reported an association between a history of pelvic inflammatory disease and ovarian cancer [<a href="#rid64">64,65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A population-based study reported that occupational exposure to paint, welding, and other chemical processes was associated with an increased risk of fallopian tube carcinoma [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Meta-analyses have reported an association between diabetes and ovarian cancer (RR 1.32, 95% CI 1.14-1.52 [<a href="#rid67">67</a>] and RR 1.17, 95% CI 1.02-1.33 [<a href="#rid68">68</a>]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Spontaneous or induced abortion does not appear to be associated with an increased risk of EOC [<a href="#rid69">69</a>].</p><p></p><p class="headingAnchor" id="H6092303"><span class="h1">PROTECTIVE FACTORS</span><span class="headingEndMark"> — </span>The factors with the strongest association with a reduced risk of ovarian cancer include  (<a class="graphic graphic_table graphicRef59585" href="/z/d/graphic/59585.html" rel="external">table 3</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Bilateral salpingo-oophorectomy</p><p class="bulletIndent1"><span class="glyph">●</span>Use of oral contraceptives</p><p class="bulletIndent1"><span class="glyph">●</span>Tubal ligation</p><p class="bulletIndent1"><span class="glyph">●</span>Hysterectomy</p><p class="bulletIndent1"><span class="glyph">●</span>Breastfeeding</p><p class="bulletIndent1"><span class="glyph">●</span>Parity</p><p></p><p class="headingAnchor" id="H2860925155"><span class="h2">Bilateral salpingo-oophorectomy</span><span class="headingEndMark"> — </span>Bilateral salpingo-oophorectomy is the most effective means for reducing the risk of developing ovarian cancer, but some patients may still develop peritoneal carcinoma, which is rare. The fallopian tubes must be removed because tubal neoplasia plays an important role in the pathogenesis of EOC. The evidence for reduction of EOC and decision making regarding the procedure are reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3250.html" rel="external">"Risk-reducing salpingo-oophorectomy in patients at high risk of epithelial ovarian and fallopian tube cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14198.html" rel="external">"Elective oophorectomy or ovarian conservation at the time of hysterectomy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/91886.html" rel="external">"Opportunistic salpingectomy for ovarian, fallopian tube, and peritoneal carcinoma risk reduction"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/758.html" rel="external">"Cancer risks and management of BRCA1/2 carriers without cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3224.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and prevention of endometrial and ovarian cancer"</a>.)</p><p></p><p class="headingAnchor" id="H438806738"><span class="h2">Hysterectomy</span><span class="headingEndMark"> — </span>Hysterectomy without bilateral salpingo-oophorectomy was associated with a 20 percent reduction in the risk of ovarian cancer (odds ratio [OR] 0.81, 95% CI 0.72-0.92) in a meta-analysis of 20 studies (5 cohort, 13 case-control studies, 1 nested case-control, 1 pooled analysis of case-control studies) [<a href="#rid70">70</a>]. When preserving the ovaries, hysterectomy with opportunistic salpingectomy may be considered, but this requires a thorough review with the patient regarding risks and benefits [<a href="#rid71">71</a>].</p><p class="headingAnchor" id="H6092311"><span class="h2">Oral contraceptives</span><span class="headingEndMark"> — </span>Studies have consistently shown that prolonged use of oral contraceptives reduces the risk of ovarian cancer. There are no data regarding the use of nonoral estrogen-progestin contraceptives (ring, patch) for ovarian cancer prevention.</p><p>In a meta-analysis of 24 studies of oral contraceptive pills as primary prevention for ovarian cancer, ever-use was associated with a reduction in ovarian cancer compared with never use (OR 0.73, 95% CI 0.66-0.81), with more than 50 percent reduction among patients with ≥10 years of use [<a href="#rid72">72</a>]. The participants of this study included people who desired prevention of pregnancy and those who were attempting to reduce their risk for ovarian cancer. Other meta-analyses have reported similar benefits in patients at high risk for ovarian cancer [<a href="#rid73">73,74</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/758.html" rel="external">"Cancer risks and management of BRCA1/2 carriers without cancer", section on 'Oral contraceptives'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Ovarian cancer'</a>.)</p><p></p><p class="headingAnchor" id="H2345267356"><span class="h2">Intrauterine device</span><span class="headingEndMark"> — </span>Both the <a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">levonorgestrel</a> and copper intrauterine devices (IUD) may be associated with lower rates of ovarian carcinoma, but data are conflicting [<a href="#rid75">75</a>]. In a meta-analysis of case-control and cohort studies of IUD use and incident ovarian cancer, IUD use was associated with a reduced incidence of ovarian cancer (OR 0.68, 95% CI 0.62-0.75) [<a href="#rid76">76</a>]. However, limitations of the analysis, such as a high risk of bias in the included studies, inability to analyze the data by type of IUD and duration of use, and the potential for confounding factors, limit confidence in this finding. This is also discussed separately. (See  <a class="medical medical_review" href="/z/d/html/116579.html" rel="external">"Intrauterine contraception: Background and device types", section on 'Benefits'</a>.)</p><p class="headingAnchor" id="H1682706237"><span class="h2">Tubal ligation</span><span class="headingEndMark"> — </span>Tubal ligation is associated with a decrease in ovarian cancer risk. These data are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/91886.html" rel="external">"Opportunistic salpingectomy for ovarian, fallopian tube, and peritoneal carcinoma risk reduction", section on 'Efficacy of tubal ligation in cancer reduction'</a>.) </p><p class="headingAnchor" id="H6092327"><span class="h2">Breastfeeding</span><span class="headingEndMark"> — </span>In a meta-analysis including 5 cohort and 35 case-control studies on the association between breastfeeding and ovarian cancer, breastfeeding was associated with a 30 percent reduction in ovarian cancer compared with not breastfeeding (OR 0.70, 95% CI 0.64-0.76) [<a href="#rid77">77</a>]. The magnitude of risk reduction increased with the total duration of breastfeeding: for &lt;6, 6 to 12, and &gt;12 months, the reductions were 15, 27, and 36 percent, respectively. </p><p>In another meta-analysis, compared with nulliparous patients with no history of breastfeeding, the combined effect of two births and &lt;6 months of breastfeeding resulted in 50 percent reduction in EOC [<a href="#rid78">78</a>].</p><p class="headingAnchor" id="H585117803"><span class="h2">Parity</span><span class="headingEndMark"> — </span>Parous patients appear to be at decreased risk for ovarian cancer compared with nulliparous patients, and the risk appears to decrease with increasing parity [<a href="#rid11">11,15,79-82</a>]. In one study, risk of EOC decreased by 8 percent for each additional pregnancy [<a href="#rid11">11</a>]. The mechanism for the reduction may be the decrease in the total number of ovulations in the parous patient's lifetime.</p><p class="headingAnchor" id="H1765111008"><span class="h2">Other</span></p><p class="bulletIndent1"><span class="glyph">●</span>A history of multiple gestation [<a href="#rid83">83-85</a>] or later age (&gt;35 years old) at last pregnancy have been associated with a reduction in risk of EOC [<a href="#rid86">86,87</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a>, but not non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) or <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>, may be associated with a reduction in ovarian cancer risk, but study results are conflicting [<a href="#rid88">88-93</a>]. There is no clear association, however, between aspirin or other NSAID use and ovarian cancer survival [<a href="#rid94">94</a>]. </p><p></p><p class="bulletIndent1">Use of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> in primary prevention of cardiovascular disease and cancers is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/16291.html" rel="external">"Aspirin in the primary prevention of cardiovascular disease and cancer", section on 'Other cancers'</a>.)</p><p></p><p class="headingAnchor" id="H6092343"><span class="h1">RISK MANAGEMENT</span></p><p class="bulletIndent1"><span class="glyph">●</span>Whether to screen and whom to screen for ovarian cancer. (See  <a class="medical medical_review" href="/z/d/html/7563.html" rel="external">"Screening for ovarian cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Approach to patients who have a family history suggestive of a hereditary ovarian cancer syndrome. (See  <a class="medical medical_review" href="/z/d/html/753.html" rel="external">"Genetic testing and management of individuals at risk of hereditary breast and ovarian cancer syndromes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a pathogenic genetic variant associated with an increased risk for ovarian cancer.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/3224.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and prevention of endometrial and ovarian cancer"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/758.html" rel="external">"Cancer risks and management of BRCA1/2 carriers without cancer"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/785.html" rel="external">"Overview of hereditary breast and ovarian cancer syndromes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients at average risk for ovarian cancer considering options for risk reduction:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/91886.html" rel="external">"Opportunistic salpingectomy for ovarian, fallopian tube, and peritoneal carcinoma risk reduction"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/14198.html" rel="external">"Elective oophorectomy or ovarian conservation at the time of hysterectomy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Ovarian cancer'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See <a class="local">'Breastfeeding'</a> above.)</p><p></p><p class="headingAnchor" id="H2022901647"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/119533.html" rel="external">"Society guideline links: Ovarian, fallopian tube, and peritoneal cancer"</a>.)</p><p class="headingAnchor" id="H6091381"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical significance</strong> – Epithelial ovarian carcinoma (EOC), fallopian tube, and peritoneal carcinomas can generally be considered one clinical entity, with some distinctions. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incidence</strong> – Ovarian cancer is the second or third most common gynecologic malignancy in many countries and has a high mortality rate. The lifetime risk of ovarian cancer in the general population is approximately 1.3 percent. (See <a class="local">'Incidence'</a> above.) </p><p></p><p class="bulletIndent1">While fallopian tube and peritoneal carcinomas were thought to be uncommon, the incidence is likely much higher because many of these carcinomas were formerly classified as advanced ovarian carcinoma but are now thought to have originated in the fallopian tube or peritoneum. (See <a class="local">'Incidence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The main risk factors for ovarian cancer include increasing age, early age at menarche or late menopause, nulliparity, endometriosis, and hereditary ovarian cancer syndromes (<em>BRCA</em> gene mutations, Lynch syndrome)  (<a class="graphic graphic_table graphicRef59585" href="/z/d/graphic/59585.html" rel="external">table 3</a>). Risk factors for fallopian tube and peritoneal carcinomas are less well defined but have generally been found to be the same. (See <a class="local">'Probable risk factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unlikely or controversial risk factors include (but are not limited to) menopausal hormone therapy, obesity, polycystic ovary syndrome (PCOS), infertility, and infertility treatments. (See <a class="local">'Unlikely or controversial risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Protective</strong> <strong>factors</strong> – Protective factors include bilateral salpingo-oophorectomy (which is the most effective protective intervention), use of oral contraceptives, intrauterine device use, tubal ligation, hysterectomy, breastfeeding, and parity  (<a class="graphic graphic_table graphicRef59585" href="/z/d/graphic/59585.html" rel="external">table 3</a>). (See <a class="local">'Probable risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk management</strong> – Decisions regarding whether to screen and whom to screen, options for patients at increased risk for ovarian cancer, and those at average risk are discussed in detail separately. (See <a class="local">'Risk management'</a> above.) </p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71:209.</a></li><li><a class="nounderline abstract_t">Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023; 73:17.</a></li><li class="breakAll">Cancer Stat Facts: Ovarian Cancer. Cancer.gov. Available at: https://seer.cancer.gov/statfacts/html/ovary.html (Accessed on September 24, 2019).</li><li><a class="nounderline abstract_t">Liao CI, Chow S, Chen LM, et al. Trends in the incidence of serous fallopian tube, ovarian, and peritoneal cancer in the US. Gynecol Oncol 2018; 149:318.</a></li><li><a class="nounderline abstract_t">Berek JS, Renz M, Kehoe S, et al. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet 2021; 155 Suppl 1:61.</a></li><li class="breakAll">Berek JS, Friedlander MF, Hacker NF. Epithelial ovarian, fallopian tube and peritoneal cancer. In: Berek &amp; Hacker’s Gynecologic Oncology, 7th, Berek JS, Hacker NF (Eds), Lippincott Williams &amp; Wilkins, 2020.</li><li><a class="nounderline abstract_t">Gates MA, Rosner BA, Hecht JL, Tworoger SS. Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol 2010; 171:45.</a></li><li><a class="nounderline abstract_t">Crijnen TE, Janssen-Heijnen ML, Gelderblom H, et al. Survival of patients with ovarian cancer due to a mismatch repair defect. Fam Cancer 2005; 4:301.</a></li><li><a class="nounderline abstract_t">Watson P, Bützow R, Lynch HT, et al. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2001; 82:223.</a></li><li><a class="nounderline abstract_t">Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA 2017; 317:2402.</a></li><li><a class="nounderline abstract_t">Tsilidis KK, Allen NE, Key TJ, et al. Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 2011; 105:1436.</a></li><li><a class="nounderline abstract_t">Sueblinvong T, Carney ME. Current understanding of risk factors for ovarian cancer. Curr Treat Options Oncol 2009; 10:67.</a></li><li><a class="nounderline abstract_t">Booth M, Beral V, Smith P. Risk factors for ovarian cancer: a case-control study. Br J Cancer 1989; 60:592.</a></li><li><a class="nounderline abstract_t">Hankinson SE, Colditz GA, Hunter DJ, et al. A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer 1995; 76:284.</a></li><li><a class="nounderline abstract_t">Wentzensen N, Poole EM, Trabert B, et al. Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. J Clin Oncol 2016; 34:2888.</a></li><li><a class="nounderline abstract_t">Salehi F, Dunfield L, Phillips KP, et al. Risk factors for ovarian cancer: an overview with emphasis on hormonal factors. J Toxicol Environ Health B Crit Rev 2008; 11:301.</a></li><li><a class="nounderline abstract_t">Kerlikowske K, Brown JS, Grady DG. Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstet Gynecol 1992; 80:700.</a></li><li class="breakAll">Jhamb N, Lambrou NC. Epidemiology and clinical presentation of ovarian cancer. In: Early diagnosis and treatment of cancer series: Ovarian cancer, Yang SC (Ed), Saunders Elsevier, Philadelphia 2010. p.1.</li><li><a class="nounderline abstract_t">Boyd J. Specific keynote: hereditary ovarian cancer: what we know. Gynecol Oncol 2003; 88:S8.</a></li><li><a class="nounderline abstract_t">Li AJ, Karlan BY. Genetic factors in ovarian carcinoma. Curr Oncol Rep 2001; 3:27.</a></li><li><a class="nounderline abstract_t">Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001; 68:700.</a></li><li><a class="nounderline abstract_t">Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005; 104:2807.</a></li><li><a class="nounderline abstract_t">Wen H, Xu Q, Sheng X, et al. Prevalence and Landscape of Pathogenic or Likely Pathogenic Germline Variants and Their Association With Somatic Phenotype in Unselected Chinese Patients With Gynecologic Cancers. JAMA Netw Open 2023; 6:e2326437.</a></li><li><a class="nounderline abstract_t">Rubin SC, Blackwood MA, Bandera C, et al. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol 1998; 178:670.</a></li><li><a class="nounderline abstract_t">Zhang S, Royer R, Li S, et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol 2011; 121:353.</a></li><li><a class="nounderline abstract_t">Friedenson B. The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers. BMC Cancer 2007; 7:152.</a></li><li><a class="nounderline abstract_t">Norquist BM, Harrell MI, Brady MF, et al. Inherited Mutations in Women With Ovarian Carcinoma. JAMA Oncol 2016; 2:482.</a></li><li><a class="nounderline abstract_t">Song H, Dicks E, Ramus SJ, et al. Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. J Clin Oncol 2015; 33:2901.</a></li><li><a class="nounderline abstract_t">Ramus SJ, Song H, Dicks E, et al. Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. J Natl Cancer Inst 2015; 107.</a></li><li><a class="nounderline abstract_t">Yarmolinsky J, Bull CJ, Vincent EE, et al. Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer. JAMA 2020; 323:646.</a></li><li><a class="nounderline abstract_t">Camargo MC, Stayner LT, Straif K, et al. Occupational exposure to asbestos and ovarian cancer: a meta-analysis. Environ Health Perspect 2011; 119:1211.</a></li><li><a class="nounderline abstract_t">Guan X, Wei R, Yang R, et al. Association of Radiotherapy for Rectal Cancer and Second Gynecological Malignant Neoplasms. JAMA Netw Open 2021; 4:e2031661.</a></li><li><a class="nounderline abstract_t">Olsen CM, Green AC, Whiteman DC, et al. Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. Eur J Cancer 2007; 43:690.</a></li><li><a class="nounderline abstract_t">Lauby-Secretan B, Scoccianti C, Loomis D, et al. Body Fatness and Cancer--Viewpoint of the IARC Working Group. N Engl J Med 2016; 375:794.</a></li><li><a class="nounderline abstract_t">Foong KW, Bolton H. Obesity and ovarian cancer risk: A systematic review. Post Reprod Health 2017; 23:183.</a></li><li><a class="nounderline abstract_t">Harris HR, Terry KL. Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review. Fertil Res Pract 2016; 2:14.</a></li><li><a class="nounderline abstract_t">Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2014; 20:748.</a></li><li><a class="nounderline abstract_t">Harris HR, Babic A, Webb PM, et al. Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 2018; 27:174.</a></li><li><a class="nounderline abstract_t">Penninkilampi R, Eslick GD. Perineal Talc Use and Ovarian Cancer: A Systematic Review and Meta-Analysis. Epidemiology 2018; 29:41.</a></li><li><a class="nounderline abstract_t">O'Brien KM, Tworoger SS, Harris HR, et al. Association of Powder Use in the Genital Area With Risk of Ovarian Cancer. JAMA 2020; 323:49.</a></li><li class="breakAll">Talc. US Food and Drug Administration. Available at: https://www.fda.gov/cosmetics/productsingredients/ingredients/ucm293184.htm (Accessed on April 22, 2019).</li><li class="breakAll">FDA In Brief: FDA Makes Progress on Efforts to Understand Presence of Asbestos in Cosmetic Products. US Food and Drug Administration. Available at: https://www.fda.gov/news-events/press-announcements/fda-brief-fda-makes-progress-efforts-understand-presence-asbestos-cosmetic-products (Accessed on October 29, 2021).</li><li class="breakAll">IARC Monographs on the Evaluation of Carcinogenic Risks to Humans:
Volume 93 Carbon Black, Titanium Dioxide, and Talc. World Health Organization. Available at: https://monographs.iarc.fr/wp-content/uploads/2018/06/mono93.pdf (Accessed on April 22, 2019).</li><li class="breakAll">Talc - Potential Risk of Lung Effects and Ovarian Cancer. Canada.ca. Available at: http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2018/68320a-eng.php (Accessed on April 22, 2019).</li><li><a class="nounderline abstract_t">Jordan SJ, Whiteman DC, Purdie DM, et al. Does smoking increase risk of ovarian cancer? A systematic review. Gynecol Oncol 2006; 103:1122.</a></li><li><a class="nounderline abstract_t">Praestegaard C, Jensen A, Jensen SM, et al. Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. Int J Cancer 2017; 140:2422.</a></li><li><a class="nounderline abstract_t">Qin LQ, Xu JY, Wang PY, et al. Milk/dairy products consumption, galactose metabolism and ovarian cancer: meta-analysis of epidemiological studies. Eur J Cancer Prev 2005; 14:13.</a></li><li><a class="nounderline abstract_t">Genkinger JM, Hunter DJ, Spiegelman D, et al. Dairy products and ovarian cancer: a pooled analysis of 12 cohort studies. Cancer Epidemiol Biomarkers Prev 2006; 15:364.</a></li><li><a class="nounderline abstract_t">Larsson SC, Orsini N, Wolk A. Milk, milk products and lactose intake and ovarian cancer risk: a meta-analysis of epidemiological studies. Int J Cancer 2006; 118:431.</a></li><li><a class="nounderline abstract_t">Myung SK, Ju W, Choi HJ, et al. Soy intake and risk of endocrine-related gynaecological cancer: a meta-analysis. BJOG 2009; 116:1697.</a></li><li><a class="nounderline abstract_t">Blank MM, Wentzensen N, Murphy MA, et al. Dietary fat intake and risk of ovarian cancer in the NIH-AARP Diet and Health Study. Br J Cancer 2012; 106:596.</a></li><li><a class="nounderline abstract_t">Yin L, Grandi N, Raum E, et al. Meta-analysis: Circulating vitamin D and ovarian cancer risk. Gynecol Oncol 2011; 121:369.</a></li><li><a class="nounderline abstract_t">Crane TE, Khulpateea BR, Alberts DS, et al. Dietary intake and ovarian cancer risk: a systematic review. Cancer Epidemiol Biomarkers Prev 2014; 23:255.</a></li><li><a class="nounderline abstract_t">Oppeneer SJ, Robien K. Tea consumption and epithelial ovarian cancer risk: a systematic review of observational studies. Nutr Cancer 2011; 63:817.</a></li><li><a class="nounderline abstract_t">Zhang D, Kaushiva A, Xi Y, et al. Non-herbal tea consumption and ovarian cancer risk: a systematic review and meta-analysis of observational epidemiologic studies with indirect comparison and dose-response analysis. Carcinogenesis 2018; 39:808.</a></li><li><a class="nounderline abstract_t">Grosso G, Bella F, Godos J, et al. Possible role of diet in cancer: systematic review and multiple meta-analyses of dietary patterns, lifestyle factors, and cancer risk. Nutr Rev 2017; 75:405.</a></li><li><a class="nounderline abstract_t">Carnide N, Kreiger N, Cotterchio M. Association between frequency and intensity of recreational physical activity and epithelial ovarian cancer risk by age period. Eur J Cancer Prev 2009; 18:322.</a></li><li><a class="nounderline abstract_t">Bertone ER, Newcomb PA, Willett WC, et al. Recreational physical activity and ovarian cancer in a population-based case-control study. Int J Cancer 2002; 99:431.</a></li><li><a class="nounderline abstract_t">Pan SY, Ugnat AM, Mao Y. Physical activity and the risk of ovarian cancer: a case-control study in Canada. Int J Cancer 2005; 117:300.</a></li><li><a class="nounderline abstract_t">Tavani A, Gallus S, La Vecchia C, et al. Physical activity and risk of ovarian cancer: an Italian case-control study. Int J Cancer 2001; 91:407.</a></li><li><a class="nounderline abstract_t">Bertone ER, Willett WC, Rosner BA, et al. Prospective study of recreational physical activity and ovarian cancer. J Natl Cancer Inst 2001; 93:942.</a></li><li><a class="nounderline abstract_t">Anderson JP, Ross JA, Folsom AR. Anthropometric variables, physical activity, and incidence of ovarian cancer: The Iowa Women's Health Study. Cancer 2004; 100:1515.</a></li><li><a class="nounderline abstract_t">Rota M, Pasquali E, Scotti L, et al. Alcohol drinking and epithelial ovarian cancer risk. a systematic review and meta-analysis. Gynecol Oncol 2012; 125:758.</a></li><li><a class="nounderline abstract_t">Lin HW, Tu YY, Lin SY, et al. Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol 2011; 12:900.</a></li><li><a class="nounderline abstract_t">Falconer H, Yin L, Salehi S, Altman D. Association between pelvic inflammatory disease and subsequent salpingectomy on the risk for ovarian cancer. Eur J Cancer 2021; 145:38.</a></li><li><a class="nounderline abstract_t">Riska A, Martinsen JI, Kjaerheim K, et al. Occupation and risk of primary fallopian tube carcinoma in Nordic countries. Int J Cancer 2012; 131:186.</a></li><li><a class="nounderline abstract_t">Zhang D, Li N, Xi Y, et al. Diabetes mellitus and risk of ovarian cancer. A systematic review and meta-analysis of 15 cohort studies. Diabetes Res Clin Pract 2017; 130:43.</a></li><li><a class="nounderline abstract_t">Lee JY, Jeon I, Kim JW, et al. Diabetes mellitus and ovarian cancer risk: a systematic review and meta-analysis of observational studies. Int J Gynecol Cancer 2013; 23:402.</a></li><li><a class="nounderline abstract_t">Dick ML, Siskind V, Purdie DM, et al. Incomplete pregnancy and risk of ovarian cancer: results from two Australian case-control studies and systematic review. Cancer Causes Control 2009; 20:1571.</a></li><li><a class="nounderline abstract_t">Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136:1184.</a></li><li><a class="nounderline abstract_t">van Lieshout LAM, Steenbeek MP, De Hullu JA, et al. Hysterectomy with opportunistic salpingectomy versus hysterectomy alone. Cochrane Database Syst Rev 2019; 8:CD012858.</a></li><li><a class="nounderline abstract_t">Havrilesky LJ, Moorman PG, Lowery WJ, et al. Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol 2013; 122:139.</a></li><li><a class="nounderline abstract_t">Iodice S, Barile M, Rotmensz N, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer 2010; 46:2275.</a></li><li><a class="nounderline abstract_t">Moorman PG, Havrilesky LJ, Gierisch JM, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol 2013; 31:4188.</a></li><li><a class="nounderline abstract_t">Minalt N, Caldwell A, Yedlicka GM, et al. Association between intrauterine device use and endometrial, cervical, and ovarian cancer: an expert review. Am J Obstet Gynecol 2023; 229:93.</a></li><li><a class="nounderline abstract_t">Wheeler LJ, Desanto K, Teal SB, et al. Intrauterine Device Use and Ovarian Cancer Risk: A Systematic Review and Meta-analysis. Obstet Gynecol 2019; 134:791.</a></li><li><a class="nounderline abstract_t">Li DP, Du C, Zhang ZM, et al. Breastfeeding and ovarian cancer risk: a systematic review and meta-analysis of 40 epidemiological studies. Asian Pac J Cancer Prev 2014; 15:4829.</a></li><li><a class="nounderline abstract_t">Sung HK, Ma SH, Choi JY, et al. The Effect of Breastfeeding Duration and Parity on the Risk of Epithelial Ovarian Cancer: A Systematic Review and Meta-analysis. J Prev Med Public Health 2016; 49:349.</a></li><li><a class="nounderline abstract_t">Stewart LM, Holman CD, Aboagye-Sarfo P, et al. In vitro fertilization, endometriosis, nulliparity and ovarian cancer risk. Gynecol Oncol 2013; 128:260.</a></li><li><a class="nounderline abstract_t">Ness RB, Grisso JA, Cottreau C, et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 2000; 11:111.</a></li><li><a class="nounderline abstract_t">Titus-Ernstoff L, Perez K, Cramer DW, et al. Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer 2001; 84:714.</a></li><li><a class="nounderline abstract_t">Hinkula M, Pukkala E, Kyyrönen P, Kauppila A. Incidence of ovarian cancer of grand multiparous women--a population-based study in Finland. Gynecol Oncol 2006; 103:207.</a></li><li><a class="nounderline abstract_t">Whiteman DC, Murphy MF, Cook LS, et al. Multiple births and risk of epithelial ovarian cancer. J Natl Cancer Inst 2000; 92:1172.</a></li><li><a class="nounderline abstract_t">Lambe M, Wuu J, Rossing MA, Hsieh CC. Twinning and maternal risk of ovarian cancer. Lancet 1999; 353:1941.</a></li><li><a class="nounderline abstract_t">Olsen J, Storm H. Pregnancy experience in women who later developed oestrogen-related cancers (Denmark). Cancer Causes Control 1998; 9:653.</a></li><li><a class="nounderline abstract_t">Pike MC, Pearce CL, Peters R, et al. Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. Fertil Steril 2004; 82:186.</a></li><li><a class="nounderline abstract_t">Whiteman DC, Siskind V, Purdie DM, Green AC. Timing of pregnancy and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2003; 12:42.</a></li><li><a class="nounderline abstract_t">Bonovas S, Filioussi K, Sitaras NM. Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis. Br J Clin Pharmacol 2005; 60:194.</a></li><li><a class="nounderline abstract_t">Trabert B, Ness RB, Lo-Ciganic WH, et al. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst 2014; 106:djt431.</a></li><li><a class="nounderline abstract_t">Baandrup L, Faber MT, Christensen J, et al. Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies. Acta Obstet Gynecol Scand 2013; 92:245.</a></li><li><a class="nounderline abstract_t">Ni X, Ma J, Zhao Y, et al. Meta-analysis on the association between non-steroidal anti-inflammatory drug use and ovarian cancer. Br J Clin Pharmacol 2013; 75:26.</a></li><li><a class="nounderline abstract_t">Murphy MA, Trabert B, Yang HP, et al. Non-steroidal anti-inflammatory drug use and ovarian cancer risk: findings from the NIH-AARP Diet and Health Study and systematic review. Cancer Causes Control 2012; 23:1839.</a></li><li><a class="nounderline abstract_t">Hurwitz LM, Webb PM, Jordan SJ, et al. Association of Frequent Aspirin Use With Ovarian Cancer Risk According to Genetic Susceptibility. JAMA Netw Open 2023; 6:e230666.</a></li><li><a class="nounderline abstract_t">Dixon SC, Nagle CM, Wentzensen N, et al. Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. Br J Cancer 2017; 116:1223.</a></li></ol></div><div id="topicVersionRevision">Topic 83387 Version 71.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33538338" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36633525" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cancer statistics, 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36633525" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cancer statistics, 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29514737" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Trends in the incidence of serous fallopian tube, ovarian, and peritoneal cancer in the US.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34669199" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cancer of the ovary, fallopian tube, and peritoneum: 2021 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34669199" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cancer of the ovary, fallopian tube, and peritoneum: 2021 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19910378" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Risk factors for epithelial ovarian cancer by histologic subtype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16341807" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Survival of patients with ovarian cancer due to a mismatch repair defect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11531271" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28632866" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21915124" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19603272" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Current understanding of risk factors for ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2679848" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Risk factors for ovarian cancer: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8625104" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A prospective study of reproductive factors and risk of epithelial ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27325851" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18368558" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Risk factors for ovarian cancer: an overview with emphasis on hormonal factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1407898" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Should women with familial ovarian cancer undergo prophylactic oophorectomy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1407898" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Should women with familial ovarian cancer undergo prophylactic oophorectomy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12586076" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Specific keynote: hereditary ovarian cancer: what we know.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11123866" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Genetic factors in ovarian carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11179017" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16284991" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37523182" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Prevalence and Landscape of Pathogenic or Likely Pathogenic Germline Variants and Their Association With Somatic Phenotype in Unselected Chinese Patients With Gynecologic Cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9579428" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21324516" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17683622" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26720728" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Inherited Mutations in Women With Ovarian Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26261251" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26315354" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32068819" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21642044" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Occupational exposure to asbestos and ovarian cancer: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33416884" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Association of Radiotherapy for Rectal Cancer and Second Gynecological Malignant Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17223544" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27557308" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Body Fatness and Cancer--Viewpoint of the IARC Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28720017" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Obesity and ovarian cancer risk: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28620541" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24688118" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29141849" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28863045" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Perineal Talc Use and Ovarian Cancer: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31910280" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Association of Powder Use in the Genital Area With Risk of Ovarian Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31910280" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Association of Powder Use in the Genital Area With Risk of Ovarian Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31910280" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Association of Powder Use in the Genital Area With Risk of Ovarian Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31910280" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Association of Powder Use in the Genital Area With Risk of Ovarian Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31910280" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Association of Powder Use in the Genital Area With Risk of Ovarian Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17005245" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Does smoking increase risk of ovarian cancer? A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28063166" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15677891" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Milk/dairy products consumption, galactose metabolism and ovarian cancer: meta-analysis of epidemiological studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16492930" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Dairy products and ovarian cancer: a pooled analysis of 12 cohort studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16052536" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Milk, milk products and lactose intake and ovarian cancer risk: a meta-analysis of epidemiological studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19775307" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Soy intake and risk of endocrine-related gynaecological cancer: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22223086" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Dietary fat intake and risk of ovarian cancer in the NIH-AARP Diet and Health Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21324518" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Meta-analysis: Circulating vitamin D and ovarian cancer risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24142805" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Dietary intake and ovarian cancer risk: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21800977" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Tea consumption and epithelial ovarian cancer risk: a systematic review of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29579174" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Non-herbal tea consumption and ovarian cancer risk: a systematic review and meta-analysis of observational epidemiologic studies with indirect comparison and dose-response analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28969358" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Possible role of diet in cancer: systematic review and multiple meta-analyses of dietary patterns, lifestyle factors, and cancer risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19390450" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Association between frequency and intensity of recreational physical activity and epithelial ovarian cancer risk by age period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11992414" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Recreational physical activity and ovarian cancer in a population-based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15898119" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Physical activity and the risk of ovarian cancer: a case-control study in Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11169967" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Physical activity and risk of ovarian cancer: an Italian case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11416116" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Prospective study of recreational physical activity and ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15042687" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Anthropometric variables, physical activity, and incidence of ovarian cancer: The Iowa Women's Health Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22449732" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Alcohol drinking and epithelial ovarian cancer risk. a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21835693" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33418235" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Association between pelvic inflammatory disease and subsequent salpingectomy on the risk for ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21805475" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Occupation and risk of primary fallopian tube carcinoma in Nordic countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28554142" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Diabetes mellitus and risk of ovarian cancer. A systematic review and meta-analysis of 15 cohort studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23354371" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Diabetes mellitus and ovarian cancer risk: a systematic review and meta-analysis of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19731050" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Incomplete pregnancy and risk of ovarian cancer: results from two Australian case-control studies and systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1476141" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31456223" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Hysterectomy with opportunistic salpingectomy versus hysterectomy alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23743450" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20537530" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24145348" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37001577" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Association between intrauterine device use and endometrial, cervical, and ovarian cancer: an expert review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31503144" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Intrauterine Device Use and Ovarian Cancer Risk: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24998548" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Breastfeeding and ovarian cancer risk: a systematic review and meta-analysis of 40 epidemiological studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27951628" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The Effect of Breastfeeding Duration and Parity on the Risk of Epithelial Ovarian Cancer: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23116937" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : In vitro fertilization, endometriosis, nulliparity and ovarian cancer risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11021606" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11237375" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Menstrual and reproductive factors in relation to ovarian cancer risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16595149" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Incidence of ovarian cancer of grand multiparous women--a population-based study in Finland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10904091" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Multiple births and risk of epithelial ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10371582" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Twinning and maternal risk of ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10189052" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Pregnancy experience in women who later developed oestrogen-related cancers (Denmark).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15237010" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12540502" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Timing of pregnancy and the risk of epithelial ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16042673" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24503200" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23240575" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22471948" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Meta-analysis on the association between non-steroidal anti-inflammatory drug use and ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22972000" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Non-steroidal anti-inflammatory drug use and ovarian cancer risk: findings from the NIH-AARP Diet and Health Study and systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36826816" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Association of Frequent Aspirin Use With Ovarian Cancer Risk According to Genetic Susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28350790" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
